Novo Nordisk (NYSE: NVO) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky 7% through 12:20 p.m. ET Tuesday after London's Financial Times reported ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy and Ozempic, according to Danish media Finans.

Novo Nordisk is still the industry leader, and its lower share price offsets a lot of the risks investors see today. Investor Alert: Our 10 best stocks to buy right now › ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

International Business News: Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 20 ...

Novo Nordisk’s share price fell on the news, trading 0.8% lower after being 4% higher earlier in the day. The shares are down 32% year-to-date and 59% from their all-time high.

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

He first joined the firm in 1991, rising to chief executive in 2017. Novo Nordisk’s share price dropped more than 5 per cent in US pre-market trading as of around 2pm CEST.

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

Novo Nordisk (NYSE: NVO) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight loss drugs announced its CEO, Lars Fruergaard Jørgensen, will step down from ...

Novo Nordisk CEO Lars Jorgensen, who led company into weight loss drugs, to step down Updated on: May 16, 2025 / 10:09 AM EDT / AP People using weight loss drugs like Ozempic and Wegovy drink less ...

Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard ...